Magna Biochem Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 22 Year, 8 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 5.55 M
- Revenue Growth -38.91%
- Profit Growth -1002.16%
- Ebitda -4790.47%
- Net Worth -4959.02%
- Total Assets -74.01%
About Magna Biochem
Magna Biochem Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 June 2002 and has a history of 22 years and eight months. Its registered office is in Narmada, Gujarat, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company has closed loans amounting to ₹5.55 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pravin Prajapati and Nirupama Prajapati serve as directors at the Company.
Company Details
- Location
Narmada, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ2002PTC040832
- Company No.
040832
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2002
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Magna Biochem?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pravin Prajapati  | Director | 23-Aug-2014 | Current |
| Nirupama Prajapati | Director | 23-Aug-2014 | Current |
Financial Performance of Magna Biochem.
Magna Biochem Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 38.91% decrease. The company also saw a substantial fall in profitability, with a 1002.16% decrease in profit. The company's net worth observed a substantial decline by a decrease of 4959.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Magna Biochem?
In 2017, Magna Biochem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹5.55 M
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.56 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Dec 2003 | Indian Overseas Bank | ₹3.75 M | Satisfied |
| 15 Mar 2003 | Indian Overseas Bank | ₹0.90 M | Satisfied |
| 15 Mar 2000 | Indian Overseas Bank | ₹0.90 M | Satisfied |
How Many Employees Work at Magna Biochem?
Unlock and access historical data on people associated with Magna Biochem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Magna Biochem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Magna Biochem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
